Nisoldipine is a calcium channel blocker of the dihydropyridine class used to treat hypertension (high blood pressure) and chronic angina pectoris (chest pain due to reduced blood flow to the heart). It works by relaxing blood vessels, improving blood flow, and reducing the heart’s workload. Nisoldipine is sold under the brand name Sular in the United States and is known for its selectivity toward cardiac blood vessels.
Parent: Nisoldipine
Impurities in nisoldipine may develop during manufacturing, storage, or handling, potentially affecting its stability and therapeutic effectiveness.
Related Substances
These are byproducts or intermediates generated during the synthesis of nisoldipine. Regulatory authorities set limits to ensure these remain within safe levels.
Degradation Products
Nisoldipine can degrade when exposed to light, heat, or moisture, which may reduce its potency. Proper storage is necessary to maintain stability.
Residual Solvents
Trace amounts of solvents used in the manufacturing process may remain in the final formulation. These are strictly monitored to meet safety standards.
Analytical Techniques for Monitoring Impurities
Techniques like High-Performance Liquid Chromatography (HPLC) and Mass Spectrometry (LC-MS) are commonly used to detect and quantify nisoldipine impurities.
Nisoldipine is primarily used for the treatment of high blood pressure (hypertension) and chronic angina. It helps lower blood pressure by relaxing blood vessels, making it easier for the heart to pump blood.
Both nisoldipine and nifedipine are calcium channel blockers used for hypertension and angina. However, nisoldipine has a longer duration of action and a greater selectivity for cardiac blood vessels, making it more effective for certain patients.
Nisoldipine and amlodipine both belong to the dihydropyridine class of calcium channel blockers. Amlodipine has a longer half-life, allowing once-daily dosing, while nisoldipine may provide better selectivity for cardiac blood vessels. The choice depends on the patient’s specific condition and medical history.
Yes, like other calcium channel blockers, nisoldipine may cause peripheral edema (swelling in the legs or ankles) due to fluid retention. If significant swelling occurs, consult a healthcare provider for dosage adjustment or alternative treatment options.
